Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cell Engineering Revenue	141.53M	173.97M	143.53M
Cell Engineering Revenue Growth	-18.65%	21.21%	-0.09%
Biosecurity Product Revenue	-	-	28.95M
Biosecurity Product Revenue Growth	-	-	-18.35%
Biosecurity Service Revenue	39.07M	53.07M	78.98M
Biosecurity Service Revenue Growth	-26.38%	-32.80%	-73.55%
Total Biosecurity Revenue	39.07M	53.07M	107.92M
Total Biosecurity Revenue Growth	-26.38%	-50.83%	-67.69%
Revenue (Total)	180.61M	227.04M	251.46M
Revenue (Total) Growth	-20.45%	-9.71%	-47.36%

EBIT

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cell Engineering Operating Income	-75.13M	-218.57M	-363.62M
Biosecurity Operating Income	-24.63M	-30.62M	-3.19M
Corporate Operating Income	-	-310.57M	-497.59M
Operating Income (Other)	-248.38M	-	-
Operating Income (Total)	-348.13M	-559.76M	-864.41M

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
New Programs	52.00	78.00
New Programs Growth	-33.33%	32.20%
Current Active Programs	176.00	162.00
Current Active Programs Growth	8.64%	44.64%
Cumulative Programs	294.00	242.00
Cumulative Programs Growth	21.49%	47.56%

Updated Sep 30, 2025. Data Source: Fiscal.ai.